Clinicopathological and prognostic significance of exosomal PD-L1 in cancer therapy.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-01-01 Epub Date: 2024-12-30 DOI:10.1080/17520363.2024.2448117

Shunqin Hu, Fengchang Huang, Xiuying Li

{"title":"Clinicopathological and prognostic significance of exosomal PD-L1 in cancer therapy.","authors":"Shunqin Hu, Fengchang Huang, Xiuying Li","doi":"10.1080/17520363.2024.2448117","DOIUrl":null,"url":null,"abstract":"Aim: The exosomal programmed death ligand-1(exoPD-L1) has recently become a topic of interest in the field of oncology. But the prognostic role of exoPD-L1 in cancer patients is inconsistent across previous studies. Therefore, a quantitative meta-analysis was performed to evaluate the prognostic and clinicopathological value of exoPD-L1 in cancer patients.Materials and methods: Twenty eligible studies were included in this study. The relationship between baseline level of exoPD-L1 and clinicopathological features, therapeutic response, overall survival (OS) and progression-free survival (PFS) was evaluated.Results: Pooled analysis indicated that high level of exoPD-L1 was significantly associated with higher tumor stage, positive lymph node metastasis, and advanced TNM stage. Elevated exoPD-L1 was associated with short OS [HR = 1.80 (1.27-2.55), p = 0.001]. In the subgroup analysis, high-level exoPD-L1 was consistently associated with poor OS in sample source, detection method, and lymphoma patients. Moreover, elevated exoPD-L1 was predictive of worse PFS [HR = 1.28 (1.13-4.18), p = 0.000]. In addition, a striking difference between cancer patients and healthy donors was observed in the level of exoPD-L1.Conclusion: exoPD-L1 is an original and effective liquid biomarker for cancer patients. However, large-scale, prospective investigations are still needed to confirm our findings.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"19 2","pages":"51-57"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2448117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The exosomal programmed death ligand-1(exoPD-L1) has recently become a topic of interest in the field of oncology. But the prognostic role of exoPD-L1 in cancer patients is inconsistent across previous studies. Therefore, a quantitative meta-analysis was performed to evaluate the prognostic and clinicopathological value of exoPD-L1 in cancer patients.

Materials and methods: Twenty eligible studies were included in this study. The relationship between baseline level of exoPD-L1 and clinicopathological features, therapeutic response, overall survival (OS) and progression-free survival (PFS) was evaluated.

Results: Pooled analysis indicated that high level of exoPD-L1 was significantly associated with higher tumor stage, positive lymph node metastasis, and advanced TNM stage. Elevated exoPD-L1 was associated with short OS [HR = 1.80 (1.27-2.55), p = 0.001]. In the subgroup analysis, high-level exoPD-L1 was consistently associated with poor OS in sample source, detection method, and lymphoma patients. Moreover, elevated exoPD-L1 was predictive of worse PFS [HR = 1.28 (1.13-4.18), p = 0.000]. In addition, a striking difference between cancer patients and healthy donors was observed in the level of exoPD-L1.

Conclusion: exoPD-L1 is an original and effective liquid biomarker for cancer patients. However, large-scale, prospective investigations are still needed to confirm our findings.

查看原文本刊更多论文

外泌体PD-L1在癌症治疗中的临床病理和预后意义。

目的：外泌体程序性死亡配体-1（exoPD-L1）近年来成为肿瘤学领域的研究热点。但在以往的研究中，exoPD-L1在癌症患者中的预后作用并不一致。因此，我们进行了一项定量荟萃分析，以评估exoPD-L1在癌症患者中的预后和临床病理价值。材料和方法：本研究纳入20项符合条件的研究。评估exoPD-L1基线水平与临床病理特征、治疗反应、总生存期（OS）和无进展生存期（PFS）之间的关系。结果：综合分析显示，高水平的exoPD-L1与肿瘤分期、淋巴结转移阳性、TNM分期明显相关。升高的exoPD-L1与较短的OS相关[HR = 1.80 (1.27-2.55), p = 0.001]。在亚组分析中，高水平的exoPD-L1与样本来源、检测方法和淋巴瘤患者的不良OS一致相关。此外，升高的exoPD-L1可预测PFS恶化[HR = 1.28 (1.13-4.18), p = 0.000]。此外，在癌症患者和健康供者之间，exoPD-L1的水平也存在显著差异。结论：exoPD-L1是一种新颖有效的癌症患者液体生物标志物。然而，仍需要大规模的前瞻性研究来证实我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.